CRISPR Therapeutics AG (CRSP)
54.85
-0.39
(-0.71%)
USD |
NASDAQ |
May 28, 16:00
54.51
-0.34
(-0.62%)
After-Hours: 20:00
CRISPR Therapeutics Cash from Investing (Quarterly): -97.80M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -97.80M |
December 31, 2023 | -81.45M |
September 30, 2023 | 121.35M |
June 30, 2023 | 216.92M |
March 31, 2023 | 117.83M |
December 31, 2022 | -175.53M |
September 30, 2022 | 87.46M |
June 30, 2022 | -56.07M |
March 31, 2022 | -114.52M |
December 31, 2021 | -8.716M |
September 30, 2021 | -565.18M |
June 30, 2021 | -293.64M |
March 31, 2021 | -167.90M |
December 31, 2020 | -204.24M |
September 30, 2020 | -330.33M |
June 30, 2020 | -3.605M |
March 31, 2020 | -2.991M |
Date | Value |
---|---|
December 31, 2019 | 7.057M |
September 30, 2019 | -2.461M |
June 30, 2019 | -2.174M |
March 31, 2019 | -1.097M |
December 31, 2018 | -1.00M |
September 30, 2018 | -0.695M |
June 30, 2018 | -0.523M |
March 31, 2018 | -0.555M |
December 31, 2017 | -0.205M |
September 30, 2017 | -3.494M |
June 30, 2017 | -1.33M |
March 31, 2017 | -3.285M |
December 31, 2016 | 14.77M |
September 30, 2016 | -1.509M |
June 30, 2016 | -1.047M |
March 31, 2016 | 19.67M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-565.18M
Minimum
Sep 2021
216.92M
Maximum
Jun 2023
-77.80M
Average
-32.39M
Median
Cash from Investing (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | -2.136B |
Novartis AG | -899.00M |
Regeneron Pharmaceuticals Inc | -1.687B |
Viking Therapeutics Inc | -459.79M |
Intellia Therapeutics Inc | 5.901M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | 109.75M |
Cash from Financing (Quarterly) | 305.93M |
Free Cash Flow | -169.05M |
Free Cash Flow Per Share (Quarterly) | 1.333 |
Free Cash Flow Yield | -3.86% |